How does it work?
The GHRH signal acts via receptors in the pituitary gland and can stimulate the release of growth hormone. The DAC modification in CJC-1295 was developed to prolong the duration of action through albumin binding; the no-DAC variant is therefore understood as a shorter GHRH analogue. This is relevant to laboratory research on the GH-IGF-1 axis, but is not a recommendation for use.
Technical mechanism
Short-acting GHRH analogue without the albumin-binding DAC modification. Research builds on GHRH(1-29) analogues and GH release.
What is being researched?
- GH response after GHRH(1-29) analogues in humans
- The difference between short-acting GHRH analogues and albumin-bound variants
- The GH-IGF-1 axis and pituitary signalling
- Regulatory and misuse-related issues around GH-modulating peptides
About the evidence: For the no-DAC variant the documentation is indirect and should be described conservatively. There are human studies on GHRH(1-29) analogues and a clear study on CJC-1295 with DAC, but these are not the same product.
Research profile
Studies and sources
The links go to independent research databases (PubMed, PubMed Central, ClinicalTrials.gov). The studies are in English and open in a new tab.
GHRH analogues and GH response
Older human studies investigated GH response after GHRH(1-29) analogues.
- Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man Clinical (human)PubMed· 1989
This study compared the bioactivity of GHRH(1-29)-NH2 and an agonist analogue after subcutaneous injection in healthy male volunteers. It is relevant as background for short-acting GHRH analogues, but is not a direct study of commercial CJC-1295 no DAC.
CJC-1295 with DAC as a contrast
The classic CJC-1295 study concerns the long-acting albumin-binding variant, not no-DAC.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Clinical (human)PubMed· 2006
This randomised study investigated CJC-1295 as a long-acting GHRH analogue in healthy adults. It showed prolonged stimulation of GH and IGF-1, precisely because of its long-acting profile. The study is used here as a contrast to the no-DAC concept, not as direct documentation for the no-DAC product.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration ReviewPubMed· 2026
This recent review discusses peptides that modulate the GH-IGF-1 axis, including GHRH analogues and the research-compound market. It is useful for regulatory and risk-based context around such substances.